Immuneering (IMRX) Operating Expenses (2020 - 2023)
Historic Operating Expenses for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to $16.3 million.
- Immuneering's Operating Expenses rose 1656.38% to $16.3 million in Q4 2023 from the same period last year, while for Sep 2024 it was $16.3 million, marking a year-over-year decrease of 7093.93%. This contributed to the annual value of $58.4 million for FY2023, which is 1254.09% up from last year.
- According to the latest figures from Q4 2023, Immuneering's Operating Expenses is $16.3 million, which was up 1656.38% from $13.9 million recorded in Q3 2023.
- In the past 5 years, Immuneering's Operating Expenses ranged from a high of $16.3 million in Q4 2023 and a low of $3.9 million during Q2 2020
- Over the past 4 years, Immuneering's median Operating Expenses value was $11.7 million (recorded in 2022), while the average stood at $10.7 million.
- Per our database at Business Quant, Immuneering's Operating Expenses soared by 11640.24% in 2021 and then skyrocketed by 544.51% in 2023.
- Quarter analysis of 4 years shows Immuneering's Operating Expenses stood at $6.0 million in 2020, then surged by 84.12% to $11.1 million in 2021, then grew by 26.01% to $14.0 million in 2022, then increased by 16.56% to $16.3 million in 2023.
- Its last three reported values are $16.3 million in Q4 2023, $13.9 million for Q3 2023, and $13.5 million during Q2 2023.